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Acute myeloid leukemia (AML) is characterized by developmental arrest, which is thought to arise from tran-
scriptional dysregulation of myeloid development programs. Hematopoietic stem and progenitor cells (HSPCs) 
isolated from human blood are frequently used as a normal comparator in AML studies. Previous studies have 
reported changes in the transcriptional program of genes involved in proliferation, differentiation, apopto-
sis, and homing when HSPCs were expanded ex vivo. The intrinsic functional differences between quiescent 
and dividing CD34+ HSPCs prompted us to determine whether fresh or cytokine-induced cord blood-derived 
CD34+ HSPCs are a more appropriate normal control compared to AML blasts. Based on principal component 
analysis and gene expression profiling we demonstrate that CD34+ HSPCs that do not undergo ex vivo expan-
sion are transcriptionally similar to minimally differentiated AML blasts. This was confirmed by comparing 
the cell cycle status of the AML blasts and the HSPCs. We suggest that freshly isolated CD34+ HSPCs that do 
not undergo ex vivo expansion would serve as a better control to identify novel transcriptional targets in the 
AML blast population.
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INTRODUCTION
Acute myeloid leukemia (AML) is characterized by 
a blockade in hematopoietic cell development, which 
is thought to arise from transcriptional dysregulation of 
myeloid developmental programs (1). Despite substantial 
advances in our understanding of the pathophysiology 
of AML more than half of all patients develop disease 
that is refractory to intensive chemotherapy. Therefore, 
new therapeutic targets need to be identified in order to 
develop new treatments to consolidate current therapy. 
Such approaches include the discovery of additional gene 
mutations that are associated with AML; however, most 
high-frequency gene mutations may have already been 
identified in AML (2). Further, as recently illustrated 
by the identification of inappropriate MET signaling in 
AML, abnormalities in this disease are not necessarily 
mutated genes (3). Messenger RNA abundances can be 
used as an alternative strategy for target identification. 
Normal human hematopoietic stem and progenitor cells 
(HSPCs) are often used either directly ex vivo as a CD34+ 
population or expanded in culture as the normal compara-
tor in these studies (4). Freshly isolated HSPCs are mostly 
in a quiescent state, while in vitro culture promotes pro-
liferation and results in changes in the transcriptional pro-
gram of genes involved in proliferation, differentiation, 
apoptosis, and homing, while long-term self-renewal does 
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not occur (5,6). Owing to these intrinsic functional dif-
ferences between quiescent and dividing CD34+ HSPCs, 
we planned to determine whether fresh or short-term 
cytokine induction of HSPCs can provide a more appro-
priate normal control compared to AML blasts.
MATERIALS AND METHODS
CD34+ HSPC Isolation and Culture
Umbilical cord blood (CB) was obtained from full-
term healthy pregnancies at the Maternity Unit of the 
University Hospital of Wales (UHW) Cardiff, following 
informed consent. Highly enriched human CD34+ cells 
(>90%) were derived from CB mononuclear cells using 
MiniMACS (Miltenyi Biotech, UK) following the man-
ufacturer’s instructions and as previously described (7). 
Confirmation of CB-derived CD34+ HSPC phenotype 
and purity were assessed by two color immunopheno-
typic analysis using anti-CD45 PerCP (Biolegend, UK) 
and CD34-PE (BD Biosciences, UK) coupled with flow 
cytometry. Freshly isolated CD34+ HSPCs were lysed in 
TRIzol® for mRNA analysis (n = 3) (see RNA Isolation). 
A paired sample was subsequently cultured for 48 h at 
1 × 105 cells/ml in Iscove’s modified Dulbecco medium 
(IMDM) containing 20% fetal calf serum (FCS) and 
the following cytokines (from R & D Systems, UK): 
interleukin 3 (IL-3; 5 ng/ml), IL-6 (10 ng/ml), stem 
cell factor (SCF; 20 ng/ml), granulocyte–macrophage 
colony-stimulating factor (GM-CSF; 5 ng/ml), granu-
locyte colony-stimulating factor (G-CSF; 5 ng/ml), and 
Flt3 ligand (5 ng/ml) as previously described (7). These 
cytokine-induced CD34+ HSPCs were then lysed in 
TRIzol® described below (n = 3).
Patient Samples
A subset of minimally differentiated (FAB-M1) AML 
blast samples (n = 6) collected from the bone marrow or 
peripheral blood of patients enrolled in the NCRI-UK 
AML clinical trial was used in this study following 
informed consent (Table 1). Samples were thawed, and 
cell viability and cell surface phenotype were analyzed 
by flow cytometry to support FAB classification. AML 
patient blast FAB-M1 subtype was confirmed using 
CD14-PE and CD15-PE (Biolegend). The samples used 
were >80% viable determined by 7-AAD (Biolegend) 
and phenotypically had low levels of CD14 and/or CD15 
cell surface markers (<10%). Flow cytometric data acqui-
sition and analysis is described below.
Cell Cycle Analysis
CD34+ HSPCs and AML blast cells were washed twice 
in ice-cold PBS and fixed with 70% ethanol for 30 min 
on ice and stored at −20oC. Fixed cells were washed free 
of alcohol and resuspended in PBS containing 40 µg/ml 
propidium iodide (Molecular Probes, Netherlands) and 
100 µg/ml RNAse type I-AS (Sigma-Aldrich, UK) fol-
lowed by incubation at 37oC for 30 min. DNA content 
was analyzed using flow cytometry (described below).
RNA Isolation and Affymetrix mRNA Gene 
Expression Profiling (GEP)
Patient AML blast and CD34+ HSPC cells were 
washed twice in ice-cold PBS and high-quality total RNA 
was extracted by lysis in TRIzol® followed by extraction 
according to the PureLink® RNA Mini Kit according to 
the manufacturer’s instructions. RNA quality, quantity, and 
purity were assessed using Agilent RNA 6000 Nano Kit 
on the Agilent 2100 Bioanalyzer (Agilent Technologies, 
UK) following the manufacturer’s instruction and as pre-
viously described (5). Only high-quality RNA [defined as 
having a RNA integrity number (RIN) >7.0 and A260/280 
ratio of ~2.0] was used in Affymetrix GEP. cDNA was 
generated from 100 ng total RNA using the Ambion 
WT Expression Kit following the manufacturer’s pro-
tocol (Applied Biosystems, UK). cDNA was subse-
quently fragmented and labeled using the Affymetrix 
GeneChip® WT Terminal Labelling Kit (Affymetrix, 
UK) and hybridized to Affymetrix Human Gene 2.0ST 
array GeneChip®. GeneChips® were subsequently washed 
and stained using the Affymetrix GeneChip® Hybridisation, 
Wash and Stain Kit (Affymetrix) followed by scanning 
on the GeneChip Scanner 3000. Data were quality con-
trolled using Affymetrix Expression Console. All the work 
Table 1. Parameters of Patients Included in Study
Patient Age Sex Cytogenetics Diagnosis
WBC 
(×109/L) Treatment
#1 (0001.CEL) 63 F Failed De novo 46 Daunorubicin 35 + cytarabine 200
#2 (0009.CEL) 56 M 46XY [20] De novo 64 ADE + GO/MACE MidAC + GO
#3 (0031.CEL) 68 F 46XX [20] De novo 114 DA (3 courses)
#4 (0038.CEL) 77 M 46XY [20] De novo 130 LDAC + ATO
#5 (0062.CE)L 49 M NK De novo 153 DA + GO 6 mg
#6 (0071.CEL) 55 F 46XX[20] De novo 77 DA60 + cytarabine 3gx1
Stratified patient parameters relating to six AML trial patients included in microarray analyses. NK, normal karyotype; WBC, white blood cell count; 
LD, low dose; ATO, arsenic trioxide; DA, daunorubicin/cytarabine. Patient microarray CEL file is identified in parentheses.
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was carried out via the Affymetrix GeneChip® profiling 
service (CBS, School of Medicine, Cardiff University). 
Data analysis is described below. Affymetrix data are 
available as Supplementary material at https://www.ebi.
ac.uk/arrayexpress/ under the following Accession No.: 
E-MTAB-3328.
Data Analysis
Flow cytometric data were acquired using the BD 
AccuriTM C6 flow cytometer, and the data were analyzed 
using FCS Express® v4 (De Novo Software, USA). Control 
stained cells were used to determine the antibody thresh-
old for the labeled cells. Debris and ejected nuclei were 
excluded from the analysis. For DNA content analysis, 
cell doublets were excluded on the basis of pulse width 
together with particles having less than 10% of 2 N DNA 
content, as previously described (8).
Raw Affymetrix intensity measurements of all the 
probe sets were exported into Partek® Genomics Suite® 
software (PGS), version 6.6 (Partek Inc., USA) for back-
ground correction, quantile normalization, and summa-
rization into gene expression level measurements using 
the Robust Multiarray Averaging (RMA) algorithm. The 
probe sets were adjusted for GC content and logged using 
base 2. The microarray analysis was carried out using 
PGS Gene Expression workflow. Quality control (QC) 
information from control and experimental probes on the 
Affymetrix chips was assessed via the QC Metrics of the 
QA/QC section of the workflow. Following QC, the data 
were preliminarily explored using principle component 
analysis (PCA). Significant genes between the contrast 
groups were calculated with one-way analysis of variance 
(ANOVA); contrast groups were (i) AML blasts versus 
freshly isolated CD34+ HSPCs, (ii) AML blasts versus 
cytokine-induced CD34+ HSPCs, and (iii) freshly isolated 
CD34+ HSPCs versus cytokine-induced CD34+ HSPCs. 
Gene lists were created between the different contrast 
groups based on their significance (>twofold, p < 0.05). 
These lists were then exported in MetaCoreTM (powered 
by Thomson Reuters GeneGo®) and analyzed for path-
way enrichment within our data set using Enrichment 
Analysis workflow.
RESULTS AND DISCUSSION
Initially, we investigated whether the transcriptome 
(using Affymetrix Human Gene 2.0ST GeneChips®) of 
freshly isolated (n = 3) (using MACS, Miltenyi Biotech) 
CD34+ HSPCs was similar to the transcriptome of the same 
population of cells that had been stimulated with cytokine 
for 48 h (n = 3), which results in one population doubling.
As shown in Figure 1a, principal component analysis 
suggests that the overall gene expression profile (GEP) of 
freshly isolated CD34+ cells is distinct from the same cells 
after cytokine stimulation. Cytokine induction changed 
the expression of 1,745 genes of which 989 and 756 genes 
were over- or underexpressed, respectively, in stimulated 
cells when compared to their freshly isolated counterparts 
(> ± twofold; p < 0.05; see Supplemental Material Table 
S1; available at: https://docs.google.com/spreadsheets/ 
d/1cvjXXimKNi50B2NDF2RmLo76K1uUUWi7P5s3 
CEreYa8/edit?usp=sharing). Pathway and gene ontology 
analysis of these changes using MetaCore® showed that 
the majority of the 10 most significant functional pro-
cesses involved genes of cell cycle and cell division 
(Tables 2 and 3). Cell cycle genes upregulated in cytokine-
induced CD34+ cells included CDK1, CDKN3, CDKN2C, 
CCNF, CCNE1, CCNE2, CCNB1, CCNB2, CCNA1, 
CNNA2, and CCNF. Chemokines and growth factors such 
as CCL1 and IL1RL1, elastase (CELA2B), phosphoserine 
aminotransferase (PSAT1) were also changed in cytokine- 
induced HSPCs.
We next analyzed minimally differentiated AML 
(FAB-M1, n = 6). This subtype has little developmental 
heterogeneity and would also be developmentally matched 
to HSPCs. We found that the AML expression profile 
more closely resembled the transcriptome of freshly iso-
lated HSPCs (Fig. 1a). Of the 494 genes that were dif-
ferent between these two groups (> ± twofold; p < 0.05), 
396 genes had a higher expression level in fresh HSPCs. 
These genes were mainly involved in cellular and system 
developmental processes (such as SNF2L1, AKT, SNF2L1, 
PAX5, DCHS1, PAM, DR6, HMGA2, SERPINE2, CNN3) 
and regulation of localization (e.g., VMAT2, DR6, GPCRs, 
HLA-DRB1, TBCD4). Genes more highly expressed in 
AML blasts were associated with cell developmental pro-
cesses (Table 2) such as cell differentiation (HOX family 
members, PBX and WT1), regulating the homotypic cell–
cell adhesion and negatively regulating the platelet aggre-
gation (PKCd, b-adrenergic receptors, and GPCRs). As 
expected from the PCA, the number of gene expression dif-
ferences between AML blasts and cytokine-treated HSPCs 
was much greater with 2,676 differently expressed genes 
(> ± twofold; p < 0.05). Similar to the differences between 
freshly isolated and cytokine-induced CD34+ cells, the 
functional pathways that changed when cytokine-induced 
CD34+ cells were compared to AML were also related to 
cell cycle and cell division (Tables 2 and 3). Genes more 
highly expressed in AML blast samples compared to divid-
ing HSPCs involved changes in regulation of transcription 
and gene expression (e.g., JMY, KLF7, PP2Aa, NF-AT5, 
MDM4, HMGB1, IRF1) or regulation of RNA and other 
cellular and metabolic processes (e.g., ZNF222, CCL5, 
TRIP8, CCND2).
Of particular note, E2F family members such as E2F1, 
E2F2, E2F4, E2F7, and E2F8, which regulate the expres-
sion of genes involved in differentiation, proliferation, 
development, and apoptosis (9), were highly expressed in 
cytokine-induced CD34+ HSPCs compared to AML blast 
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samples and unstimulated CD34+ HSPCs, thus confirming 
an induction of differentiation signature due to the cyto-
kines used. In contrast, AML blasts highly expressed genes 
(compared to HPSCs) involved in notch signaling including 
NFKB1A, and genes involved in several signal transduc-
tion pathways such as TRAF6, TLR2, IL3RA, IL11RA, and 
IL13RA, which are known to be frequently overexpressed 
in AML. b-Adrenergic receptors, known to be involved 
in several cancers (10), were also highly expressed in 
the AML patient blasts as were genes involved in the 
negatively regulating cell morphogenesis instrumental 
to cell differentiation (GO: 0010771) (PPP2CA, ULK1, 
RAPGEF2, and ARHGAP4). Most of the genes that were 
expressed in patients were involved in various phases 
of the cell cycle process and various immune responses 
compared to cytokine-induced and unstimulated CD34+ 
Figure 1. (a) The data was preliminarily explored using PCA, which maps out the principle components of the dataset and exhibits 
the degree of variance between the sample types [AML blast cells (n = 6), freshly isolated (n = 3) and cytokine-induced CD34+ cells 
(n = 3)]. (b) Cells were fixed and stained with propidium iodide to estimate the DNA content of HSPCs and AML cells using flow 
cytometry. The G0/1, S, and G2 phase are depicted with a PI-area histogram for CD34+ HSPC and AML blast cells. The percentage of 
analyzed cells with its DNA content is indicated in each panel: (i) CD34+ HSPC fresh quiescent, (ii) CD34+ cytokine-induced dividing 
HSPCs, and (iii) AML blast cells.
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HSPCs, respectively (see Supplementary Material Table 
S2 and Table S3; available at: https://docs.google.com/
spreadsheets/d/1cvjXXimKNi50B2NDF2RmLo76K1uU
UWi7P5s3CEreYa8/edit?usp=sharing).
The GEP data above suggest that when CD34+ cells 
are stimulated with cytokine for 48 h, the transcrip-
tional program of the cells invokes changes in cell 
cycle/division transcription as would be expected. 
AML blasts have a transcriptional program similar 
to freshly isolated CD34+ cells, which are withdrawn 
from cell cycle. To support these data, we analyzed the 
cell cycle status of each of the populations using flow 
cytometry and analysis of DNA content. As shown in 
Figure 1b, the majority of AML cells and freshly iso-
lated CD34+ HSPCs were in G0/G1. In contrast, over 
50% of the cytokine-induced HSPCs were in S and 
G2M phases. This is in concordance with the work of 
Lucotti et al. (11), where they compared the cell cycle 
status of cord blood-derived freshly harvested and cul-
tured (up to 24 h) CD34+ HSPCs.
Table 2. Top 10 Gene Ontology Processes Altered Between AML Blasts, Cytokine-Induced and Fresh (Unstimulated) CD34+ HSPCs 
Sorted by “Statistically Significant Processes” Set Obtained From GeneGo® via Metacore® (Thomson Reuters)
# Process Total Genes In Data p Value FDR
Cytokine-induced HSPCs versus unstimulated CD34+ HSPCs
1 Cell cycle 1,600 316 3.15 × 10−65 2.44 × 10−61
2 Cell cycle process 1,263 258 1.80 × 10−55 6.97 × 10−52
3 Mitotic cell cycle 969 220 3.69 × 10−55 9.53 × 10−52
4 DNA metabolic process 1,072 220 2.58 × 10−47 5.00 × 10−44
5 Organelle organization 3,144 434 1.64 × 10−44 2.40 × 10−41
6 Mitotic cell cycle process 890 192 1.86 × 10−44 2.40 × 10−41
7 Nuclear division 577 148 1.39 × 10−43 1.54 × 10−40
8 Mitotic nuclear division 381 117 5.92 × 10−43 5.73 × 10−40
9 Organelle fission 608 151 1.30 × 10−42 1.12 × 10−39
10 Cell division 803 174 1.69 × 10−40 1.31 × 10−37
AML blast cells versus unstimulated CD34+ cells
1 System development 5,219 204 1.53 × 10−66 1.29 × 10−62
2 Anatomical structure 
morphogenesis
2,751 136 1.26 × 10−63 5.33 × 10−60
3 Regulation of multicellular 
organismal process
2,991 142 3.12 × 10−62 8.79 × 10−59
4 Multicellular organismal 
development
6,004 221 6.29 × 10−62 1.33 × 10−58
5 Organ development 3,922 164 1.42 × 10−57 2.41 × 10−54
6 Developmental process 6,723 233 1.18 × 10−56 1.66 × 10−53
7 Single-organism 
developmental process
6,670 231 1.67 × 10−56 2.02 × 10−53
8 Anatomical structure 
development
5,993 214 3.31 × 10−55 3.50 × 10−52
9 Organ morphogenesis 1,176 74 6.61 × 10−54 6.21 × 10−51
10 Tube development 849 60 2.33 × 10−50 1.81 × 10−47
AML blast cells versus cytokine-induced CD34+ cells
1 Mitotic cell cycle 969 289 1.53 × 10−66 1.29 × 10−62
2 Cell cycle 1,600 390 1.26 × 10−63 5.33 × 10−60
3 Cellular metabolic process 10,409 1,451 3.12 × 10−62 8.79 × 10−59
4 Cell cycle process 1,263 332 6.29 × 10−62 1.33 × 10−58
5 Organic substance 
metabolic process
10,968 1,493 1.42 × 10−57 2.41 × 10−54
6 Primary metabolic process 10,669 1,460 1.18 × 10−56 1.66 × 10−53
7 Mitotic cell cycle process 890 258 1.67 × 10−56 2.02 × 10−53
8 Metabolic process 12,130 1,600 3.31 × 10−55 3.50 × 10−52
9 DNA metabolic process 1,072 285 6.61 × 10−54 6.21 × 10−51
10 Nitrogen compound 
metabolic process
6,753 1,019 2.33 × 10−50 1.81 × 10−47
Total Genes refers to the total number of genes in the GO process of the Human Gene 2.0 ST genome. In Data refers to the number of genes from the 
dataset that are involved in the GO process. p Value ranks the GO process based on a probability to have the given value of actual or higher (or lower 
for negative z score). GO Processes are ranked according to false discovery rate (FDR) ensuring that no more than 5% of significant terms are false 
positive. The GO processes are not mutually exclusive in terms of containing a gene.
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This study shows for the first time that the GEP of 
CD34+ cells that do not undergo ex vivo expansion are 
the best match for the GEP of minimally differentiated 
AML blasts and would serve as a better control to iden-
tify novel targets in the AML blast population. AML blast 
cells are usually banked or cryopreserved for preclinical 
studies and exhibit a quiescent phenotype upon thawing. 
However, a study by Hess et al. (12) found no significant 
differences in the GEP of fresh versus frozen AML blasts. 
Thus, freshly isolated, quiescent CD34+ HSPCs are the 
more appropriate control for transcriptomic studies for 
minimally differentiated AML blasts. This would likely 
also be the case for other “omic” technologies where 
the analysis is much more demanding of the amount of 
biologic material, posing a significant limitation in these 
studies. Nonetheless, there are opportunities for the use 
of the data derived to target analysis of specific proteins 
that may be differentially expressed between apparently 
normal quiescent primitive hematopoietic cells and their 
AML counterparts; this can be achieved with new tech-
nologies such as micro-Western blotting (13). In the pres-
ent study genes such as adrenoreceptors, EVI1 (regulates 
self-renewal in hematopoietic stem cell compartment), 
Homeobox genes (regulate development) are found to be 
differentially expressed. Using immunocytohistochem-
istry or micro-Western blotting we can gain insight into 
the changing patterns of such expression between these 
populations knowing we have now identified an appro-
priate control population.
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